Jeffrey A. Barnes, Ph.D.
Affiliations: | 2004 | University of Illinois, Urbana-Champaign, Urbana-Champaign, IL |
Google:
"Jeffrey Barnes"Mean distance: 17.58 (cluster 32)
Parents
Sign in to add mentor| Martha Ulbrick Gillette | grad student | 2004 | UIUC | |
| (Conservation of Timeless in the mammalian circadian clock.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Haydu JE, Maron JS, Redd RA, et al. (2022) Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Advances |
| Soumerai JD, Mato AR, Dogan A, et al. (2021) Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet. Haematology. 8: e879-e890 |
| Soumerai JD, Mato AR, Carter J, et al. (2020) Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax. Journal of Clinical Oncology. 38: 8006-8006 |
| Abramson JS, Irwin KE, Frigault MJ, et al. (2019) Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer |
| Abramson JS, Arnason JE, LaCasce AS, et al. (2019) Brentuximab Vedotin, Doxorubicin, Vinblastine and Dacarbazine for Non-bulky Limited Stage Classical Hodgkin Lymphoma. Blood |
| Karschnia P, Jordan JT, Forst DA, et al. (2019) Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood |
| Karmali R, Abramson JS, Stephens DM, et al. (2019) Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report. Journal of Clinical Oncology. 37: 7542-7542 |
| Karmali R, Abramson JS, Stephens DM, et al. (2019) Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation Blood. 134: 3990-3990 |
| Barnes JA, Redd R, Fisher DC, et al. (2018) Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. Hematological Oncology |
| Abramson JS, Redd RA, Barnes JA, et al. (2018) A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma Blood. 132: 1654-1654 |